Enhancing Personalised Care in HR+ Early Breast Cancer: How MGAs Help to Individualise Risk-based Systematic Treatment Decisions
Speakers
Prof. Giampaolo Bianchini
Italy
Prof. Shani Paluch-Shimon
Israel
PD Dr. Mattea Reinisch
Germany
Agenda
12:15 – 12:20
Welcome and Introduction
Giampaolo Bianchini
12:20 – 12:35
Prognosis vs Prediction: Does high-risk mean high response?
Shani Paluch-Shimon
12:35 – 15:50
Incorporating genomic testing when considering adjuvant CDK4/6 inhibitor
Giampaolo Bianchini
12:50 – 13:05
Where are we with personalised approaches for node-positive patients?
Mattea Reinisch
13:05 – 13:15
Panel discussion / Q&A
Giampaolo Bianchini, Shani Paluch-Shimon, Mattea Reinisch
Visit us at Booth 24
More than 2 million patients globally have benefited from insights provided by the Oncotype DX Breast Recurrence Score® test, supporting a more individualised approach to care in early-stage breast cancer.
Join us at Booth 24 to learn more about the clinical utility of the Oncotype DX® test and its role in supporting treatment decisions for patients with early-stage HR+/HER2- breast cancer.
We look forward to welcoming you at ESMO Breast Cancer 2026.